Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study.

Clin Kidney J · 2024 · PMC11464987 · PMID 39391591

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

Hgb levels showed an increasing trend in the whole telitacicept group and the newly treated telitacicept subgroup, but a decreasing trend was observed in the conventional IS group.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.